{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T07:02:43Z","timestamp":1772434963440,"version":"3.50.1"},"reference-count":33,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the short-term clinical efficacy and safety of efgartigimod in the treatment of Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) in a real-world setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective real-world study enrolled 12 CIDP patients receiving efgartigimod treatment at the Department of Neurology, The First Affiliated Hospital of Chongqing Medical University. Efficacy was comprehensively assessed using the Medical Research Council (MRC) scale for muscle strength, the inflammatory Rasch-built Overall Disability Scale (I-RODS) for disability, and the Inflammatory Neuropathy Cause and Treatment (INCAT) scale. Assessments were performed before the first dose and one week after each subsequent dose. Adverse events during treatment, concomitant use of other immunosuppressants, routine laboratory tests, electrocardiograms, and immunoglobulin levels before and after treatment were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Among the 12 patients, 50% received subcutaneous injection and 50% received intravenous infusion of efgartigimod. During the follow-up period, significant efficacy was observed overall, MRC scores increased from 45.92 \u00b1 15.69 to 55.00 \u00b1 10.14, I-RODS scores increased from 49.25 \u00b1 24.21 to 75.42 \u00b1 28.46, and INCAT scores decreased from 4.42 \u00b1 3.20 to 1.42 \u00b1 2.61. By the end of the follow-up at the fifth week after the first dose, 11 patients (91.7%) achieved clinical improvement. No significant difference in efficacy was found between the subcutaneous and intravenous administration routes. Laboratory tests showed a downward trend in IgG levels after treatment, with no significant decrease in albumin. The incidence of adverse events during treatment was low, with only one patient experiencing a localized rash.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study demonstrates the short-term efficacy and safety of efgartigimod in treating CIDP, suggesting its potential as a safe and effective alternative therapy. Further exploration is needed to determine its suitability for long-term maintenance treatment of CIDP.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1779544","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:32:41Z","timestamp":1772433161000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A prospective real-world study of efgartigimod in the treatment of chronic inflammatory demyelinating polyradiculoneuropathy"],"prefix":"10.3389","volume":"17","author":[{"given":"Xiangtao","family":"Nie","sequence":"first","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Neurology, People\u2019s Hospital of Chongqing Hechuan","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yongbo","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Neurology, Bazhong Central Hospital","place":["Bazhong, Sichuan, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Geke","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Qi","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Han","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wanying","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lei","family":"Hao","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiuming","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Neurology, The First Affiliated Hospital of Chongqing Medical University","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2019-320314","article-title":"Chronic inflammatory demyelinating polyneuropathy: update on diagnosis, immunopathogenesis and treatment","volume":"90","author":"Lehmann","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1111\/ene.14959","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force\u2014Second revision","volume":"28","author":"Van den Bergh","year":"2021","journal-title":"Eur J Neurol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09998-8","article-title":"Systematic literature review of burden of illness in chronic inflammatory demyelinating polyneuropathy (CIDP)","volume":"268","author":"Querol","year":"2020","journal-title":"J Neurol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-020-09823-2","article-title":"Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features","volume":"268","author":"Tang","year":"2020","journal-title":"J Neurol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1097\/WCO.0000000000000725","article-title":"Autoantibodies in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"32","author":"Pascual-Go\u00f1i","year":"2019","journal-title":"Curr Opin Neurol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.cca.2015.02.039","article-title":"Autoimmune peripheral neuropathies","volume":"449","author":"Bourque","year":"2015","journal-title":"Clin Chimica Acta"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jneuroim.2014.11.022","article-title":"Characterization of a new rat model for chronic inflammatory demyelinating polyneuropathies","volume":"278","author":"Brun","year":"2015","journal-title":"J Neuroimmunol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurol.2016.05.006","article-title":"Chronic inflammatory demyelinating polyradiculoneuropathy: A new animal model for new therapeutic targets","volume":"172","author":"de S\u00e8ze","year":"2016","journal-title":"Rev Neurol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2021.103019","article-title":"Efficacy of intravenous immunoglobulin in autoimmune neurological diseases. Literature systematic review and meta-analysis","volume":"21","author":"Morales-Ruiz","year":"2022","journal-title":"Autoimmun Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"Cd003906","DOI":"10.1002\/14651858.CD003906.pub4","article-title":"Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy","volume":"2015","author":"Mehndiratta","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"key":"B11","doi-asserted-by":"publisher","first-page":"3048","DOI":"10.3390\/ijms22063048","article-title":"In translation: FcRn across the therapeutic spectrum","volume":"22","author":"Qi","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01175-7","article-title":"Neonatal Fc receptor-targeted therapies in neurology","volume":"19","author":"Nelke","year":"2022","journal-title":"Neurother: J Am Soc Exp Neurother"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01540","article-title":"The neonatal Fc receptor (FcRn): A misnomer","volume":"10","author":"Pyzik","year":"2019","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.015","article-title":"Neonatal Fc receptor in human immunity: Function and role in therapeutic intervention","volume":"146","author":"Patel","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1172\/JCI97911","article-title":"Lykhopiy V et\u00a0al: Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans","volume":"128","author":"Ulrichts","year":"2018","journal-title":"J Clin Invest"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2019.102366","article-title":"Next-generation Fc receptor-targeting biologics for autoimmune diseases","volume":"18","author":"Zuercher","year":"2019","journal-title":"Autoimmun Rev"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-022-01678-3","article-title":"Efgartigimod: first approval","volume":"82","author":"Heo","year":"2022","journal-title":"Drugs"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(24)00309-0","article-title":"Safety, tolerability, and efficacy of subcutaneous efgartigimod in patients with chronic inflammatory demyelinating polyradiculoneuropathy (ADHERE): a multicentre, randomised-withdrawal, double-blind, placebo-controlled, phase 2 trial","volume":"23","author":"Allen","year":"2024","journal-title":"Lancet Neurol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/17562864241311127","article-title":"Application of efgartigimod in Chinese patients with myasthenia gravis: a single-center real-world prospective study","volume":"18","author":"Zhu","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1418503","article-title":"Efgartigimod as a promising add-on therapy for myasthenic crisis: a prospective case series","volume":"15","author":"Song","year":"2024","journal-title":"Front Immunol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1533167","article-title":"Short-term treatment of CIDP with efgartigimod: a case series in China","volume":"16","author":"Sun","year":"2025","journal-title":"Front Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2024.1472845","article-title":"Efgartigimod treatment for generalized myasthenia gravis: a single-center case series of 16 patients","volume":"15","author":"Nomura","year":"2024","journal-title":"Front Neurol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578558","article-title":"Response of refractory residual ocular symptoms to efgartigimod in generalized myasthenia gravis: A real-world case series","volume":"401","author":"He","year":"2025","journal-title":"J Neuroimmunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1447182","article-title":"Treatment of refractory immune-mediated necrotizing myopathy with efgartigimod","volume":"15","author":"Yang","year":"2024","journal-title":"Front Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e200216","DOI":"10.1212\/NXI.0000000000200216","article-title":"Membrane proteome-Wide screening of autoantibodies in CIDP using human cell microarray technology","volume":"11","author":"Caballero-\u00c1vila","year":"2024","journal-title":"Neurol (R) Neuroimmunol Neuroinflamm"},{"key":"B27","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/ene.14133","article-title":"Antibody- and macrophage-mediated segmental demyelination in chronic inflammatory demyelinating polyneuropathy: clinical, electrophysiological, immunological and pathological correlates","volume":"27","author":"Vallat","year":"2020","journal-title":"Eur J Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"6394","DOI":"10.3390\/jcm11216394","article-title":"New targeted agents in myasthenia gravis and future therapeutic strategies","volume":"11","author":"S\u00e1nchez-Tejerina","year":"2022","journal-title":"J Clin Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/mus.26772","article-title":"A population-based study of long-term outcome in treated chronic inflammatory demyelinating polyneuropathy","volume":"61","author":"Al-Zuhairy","year":"2020","journal-title":"Muscle Nerve"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/jns.12344","article-title":"Clinical factors, diagnostic delay, and residual deficits in chronic inflammatory demyelinating polyradiculoneuropathy","volume":"24","author":"Bunschoten","year":"2019","journal-title":"J Peripher Nervous Syst: JPNS"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12860-w","article-title":"Early therapy initiation is crucial in chronic inflammatory demyelinating polyneuropathy: prospective multimodal data from the German INHIBIT registry","volume":"272","author":"Schumacher","year":"2025","journal-title":"J Neurol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"e000651","DOI":"10.1136\/bmjno-2024-000651","article-title":"Long-term follow-up of relapse and remission of CIDP in a Chinese cohort","volume":"6","author":"Niu","year":"2024","journal-title":"BMJ Neurol Open"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-024-12548-1","article-title":"Preventing long-term disability in CIDP: the role of timely diagnosis and treatment monitoring in a multicenter CIDP cohort","volume":"271","author":"Quint","year":"2024","journal-title":"J Neurol"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1779544\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:32:42Z","timestamp":1772433162000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1779544\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":33,"alternative-id":["10.3389\/fimmu.2026.1779544"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1779544","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1779544"}}